To study early treatment response in peripheral blood on Day 15 in B cell Acute Lymphoblastic Leukemia patients
Not Applicable
Completed
- Conditions
- Health Condition 1: null- B cell Acute Lymphoblastic Leukemia
- Registration Number
- CTRI/2016/08/007180
- Lead Sponsor
- Tata Memorial Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 100
Inclusion Criteria
B acute lymphoblastic leukemia patients treated on Indian Childhood Collaborative Leukemia group(ICiCLe)protocol
Exclusion Criteria
Patients with following high risk cytogenetics-
(i) MLL rearranged leukaemias, e.g. t(4;11) (q21;q23)
(ii) Low hypodiploidy ( <45 chromosomes)
(iii) t(17;19) (q22;p13) (TCF3-HLF)
(iv) Intrachromosomal amplification of chromosome 21 (iAMP21)
(v) t(9;22) (q34;q11) (BCR-ABL)
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method evel of MRD by manual analysis and automated analysis on day 15 post induction peripheral blood (%) and categorization into-MRD (Day15 PB) positive/negativeTimepoint: Day 15 post induction
- Secondary Outcome Measures
Name Time Method 4 year relapse and survival rates for B- ALL patients based on Day 15 and post induction MRD. (This will not be a part of student thesis)Timepoint: 4 years from start of treatment